BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 29083228)

  • 41. Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers.
    Linklater ES; Tovar EA; Essenburg CJ; Turner L; Madaj Z; Winn ME; Melnik MK; Korkaya H; Maroun CR; Christensen JG; Steensma MR; Boerner JL; Graveel CR
    Oncotarget; 2016 Oct; 7(43):69903-69915. PubMed ID: 27655711
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inhibitory action of naphtho[1,2-b]furan-4,5-dione on hepatocyte growth factor-induced migration and invasion of MDA-MB-231 cells: mechanisms of action.
    Tsai PC; Chu CL; Tseng CH; Chen YL; Chang LS; Lin SR
    Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):716-26. PubMed ID: 24909202
    [TBL] [Abstract][Full Text] [Related]  

  • 43. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
    Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
    Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nafamostat mesilate negatively regulates the metastasis of triple-negative breast cancer cells.
    Mander S; You DJ; Park S; Kim DH; Yong HJ; Kim DS; Ahn C; Kim YH; Seong JY; Hwang JI
    Arch Pharm Res; 2018 Feb; 41(2):229-242. PubMed ID: 29196918
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
    Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
    Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
    [No Abstract]   [Full Text] [Related]  

  • 46. Anti-tumorigenic effects of a novel digitoxin derivative on both estrogen receptor-positive and triple-negative breast cancer cells.
    Kulkarni YM; Yakisich JS; Azad N; Venkatadri R; Kaushik V; O'Doherty G; Iyer AKV
    Tumour Biol; 2017 Jun; 39(6):1010428317705331. PubMed ID: 28618929
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer.
    Sun ZJ; Wu Y; Hou WH; Wang YX; Yuan QY; Wang HJ; Yu M
    Oncotarget; 2017 Apr; 8(17):29067-29079. PubMed ID: 28404966
    [TBL] [Abstract][Full Text] [Related]  

  • 48. hMAGEA2 promotes progression of breast cancer by regulating Akt and Erk1/2 pathways.
    Park S; Sung Y; Jeong J; Choi M; Lee J; Kwon W; Jang S; Park SJ; Kim HS; Lee MH; Kim DJ; Liu K; Kim SH; Dong Z; Ryoo ZY; Kim MO
    Oncotarget; 2017 Jun; 8(23):37115-37127. PubMed ID: 28415749
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibition on the growth of human MDA-MB-231 breast cancer cells in vitro and tumor growth in a mouse xenograft model by Se-containing polysaccharides from Pyracantha fortuneana.
    Yuan C; Wang C; Wang J; Kumar V; Anwar F; Xiao F; Mushtaq G; Liu Y; Kamal MA; Yuan D
    Nutr Res; 2016 Nov; 36(11):1243-1254. PubMed ID: 27865619
    [TBL] [Abstract][Full Text] [Related]  

  • 50. ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.
    Ding J; Wen W; Xiang D; Yin P; Liu Y; Liu C; He G; Cheng Z; Yin J; Sheng C; Zhang W; Nan F; Ye W; Zhang X; Wang H
    Oncotarget; 2015 May; 6(13):11627-39. PubMed ID: 25890498
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC).
    Godugu C; Doddapaneni R; Singh M
    Colloids Surf B Biointerfaces; 2017 May; 153():208-219. PubMed ID: 28249200
    [TBL] [Abstract][Full Text] [Related]  

  • 52. p38γ MAPK Is a Therapeutic Target for Triple-Negative Breast Cancer by Stimulation of Cancer Stem-Like Cell Expansion.
    Qi X; Yin N; Ma S; Lepp A; Tang J; Jing W; Johnson B; Dwinell MB; Chitambar CR; Chen G
    Stem Cells; 2015 Sep; 33(9):2738-47. PubMed ID: 26077647
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Polyphenol-Rich Extract From Muscadine Grapes Inhibits Triple-Negative Breast Tumor Growth.
    Collard M; Gallagher PE; Tallant EA
    Integr Cancer Ther; 2020; 19():1534735420917444. PubMed ID: 32578460
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown.
    Previdi S; Abbadessa G; Dalò F; France DS; Broggini M
    Mol Cancer Ther; 2012 Jan; 11(1):214-23. PubMed ID: 22027690
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer.
    Hsu YH; Yao J; Chan LC; Wu TJ; Hsu JL; Fang YF; Wei Y; Wu Y; Huang WC; Liu CL; Chang YC; Wang MY; Li CW; Shen J; Chen MK; Sahin AA; Sood A; Mills GB; Yu D; Hortobagyi GN; Hung MC
    Cancer Res; 2014 Sep; 74(17):4822-35. PubMed ID: 24970481
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
    Takai K; Le A; Weaver VM; Werb Z
    Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dipalmitoylphosphatidic acid inhibits tumor growth in triple-negative breast cancer.
    Zhang QQ; Chen J; Zhou DL; Duan YF; Qi CL; Li JC; He XD; Zhang M; Yang YX; Wang L
    Int J Biol Sci; 2017; 13(4):471-479. PubMed ID: 28529455
    [TBL] [Abstract][Full Text] [Related]  

  • 58. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
    Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
    Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Stimulation of triple negative breast cancer cell migration and metastases formation is prevented by chloroquine in a pre-irradiated mouse model.
    Bouchard G; Therriault H; Geha S; Bérubé-Lauzière Y; Bujold R; Saucier C; Paquette B
    BMC Cancer; 2016 Jun; 16():361. PubMed ID: 27282478
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapeutic Targeting of Stromal-Tumor HGF-MET Signaling in an Organotypic Triple-Negative Breast Tumor Model.
    Singh S; Lamichhane A; Rafsanjani Nejad P; Heiss J; Baumann H; Gudneppanavar R; Leipzig ND; Konopka M; Luker GD; Tavana H
    Mol Cancer Res; 2022 Jul; 20(7):1166-1177. PubMed ID: 35348758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.